溃疡性结肠炎和克罗恩病的英夫利西(类克)治疗效果比较.pdf

1、Y T : W , Enullmai:l lishirong2000 yahoo. com. cn X 6 h ( X ) r T 1 李世荣,陆晓娟,盛剑秋,范如英,李恕军,赵晓军北京军区总医院消化科,北京 100700nullK 1 null “ s a1 7 CD 7 UC ( X ) r T bZ E 5mg/kg, 0a2a6 , 8 % B Q Z E X b S = M i n r ,s Y 9 ) - ESR CRP b T 7 CD , 4 r , 3 z b 1 r * b7 UC , 3 r , 4 z , 2 * b14 CD UC , h y 4 U “ 5 = /

2、h M A z b i CD UC X r T K z b m 0 V CD ? b1 ? 3 V Q b X 4 CD UC M r T bnull1 o M null CD; UC; F m s | : R574. 62 D S M : A c I | : 1006- 5709(2010) 07- 0644- 04 l : 2010null06null02Comparison of the treating effects of infliximab in Crohn! s disease and ulcerative colitisLIShirong, LU X iaojuan, SHE

3、NG Jianqiu, FAN Ruying, LIShujun, ZHAO XiaojunDepartment ofGastroenterology, theM ilitaryGeneralHospital ofBeijing PLA, Beijing 100700, ChinanullAbstractnull Objective To analyze and compare the effects of infliximab (Remicade) in CD andUC patients. M ethnullods Fourteen cases ( 7 CD and 7UC) receiv

4、ed intravenous Remicade infusions on the protocolof5 mg/kg, 0, 2, 6weeks and then every 8weeks. The evaluation ofeffects based on theChineseGastroenterologicalAssociation IBD groupConsensus. Before and after the therapy, ESR and CRPwere recorded in the patientsw ith remissive and activephase ofdisea

5、ses. Results In 7 cases ofCD patients, 4 patients achieved rem ission, 3 patients improved, 2 caseswasmucosalhealing. In 7 cases ofUC patients, 3 patients achieved remission, 4 patients improved, one casewasmucosalhealing.In all the 14 patients, the patientswho had rapid disappearance of symptoms af

6、ter the therapymay get discovery ofmunullcosal lesion. TheCD patientsw ithout any complications had the best result byRem icade. Administration ofRemicadeafter intestinal resective surgery was effective at preventing recurrence of CD. Only 1 case appeared hypersensitivity.Conclusion Remicade has sim

7、ilar bettereffects on intractable CD andUC.nullKey wordsnull Crohn! s disease; U lcerative colitis; Infliximab M F G (UC) X 6 h (CD) m 9 , 4 4 U , 1M UC 25%M G , 30% 1m 1b s ? E m , 3 - 4 / , r T M 1 % 4 5 b“ - X , % y 0 ,+ Y ? y 0 nullnull(TNFnullnull) CD UC ? 3 V ? “1 o T 2b TNFnullnullL V F 3 ? 3

8、 b X (Remicade) B null 3 8 TNFnullnull f o G1 F , V r TNF % 3,V 7 V y h bv D A U , _ 3 4 V r F G UC CD4null7b 7 ,S = C 1 X UC 4 ,+ Y CD UC r 1 b | 1 s 14 h ( 7 UC 7 CD) X r T b1 Z E1. 1 h 4 4 “ 7 b b F ( 8 4 1 p ,i ( 28. 35 ( 1. 5 57 ); ( h 18 ( 2 48 ); 4 F , 3 h b7 UC ( 3 ; ( 28. 35 ( 1. 5 57 ); (

9、h 35 (2 53 ), F UCh b F - f nV 1b1. 2 4 ! 9 4 F - 1 = s _ , H _ a U aL ? a / ? a aCRPa aPPD k b ( 3Q X ) / K B Q X , _ - “ b1. 3 Z E “ 2 B Q 0 H , 3mg/kg X , ( 5 mg/kg, 0a2a6 T , , 8 B Q ,T % b1. 4 r s Y HarveynullBradshow ( CD )Sutherland (UC) 8 s 9 r T ,1 - aCRPM ,i * f b1. 5 d 9 s _ 1 - ESRCRPM b

10、P , r * , 1 2Q , “5 A z , ? b4 y E ,m 0 , 6 12 , 3 n % h ? , 1 E f / , s 2Q , E F , m (X M )b7 ,O ESR CRP A / , ( A U “ 5 = / h M z , S / Q 7 6 , CRP ( / 28. 63b3 ) ESR ( 6 7. 67, _ T Z = - 1. 014aP= 0. 310; CRP ( 6 4. 73, _ T Z =- 1. 352aP = 0. 176b5 UC F , 2 F b1 8Q , 4 X s 4Q ( ), 2 X s 2Q ( 1 )b

11、 H W 1 16 bV V 3 V A , X z ,i V T f 4 b3 B Q 0 3? , 4 7 14? A z b h y , / h Mg A z , . * b CDM ,O ESR CRP A / , ( A U “ 5 = / h Mz , S / Q 7 6 ,4 U r D b2 UC B Q 3mg/kg 0 , z A , = Q 5 mg/kg, , Az , ( S M i n 9 0 , i r T b Sutherland 3 , - , ESR ( / 4. 33; CRP ( / 12. 13b3 ) , ESR ( 6 3, _ T Z=- 0.

12、730aP = 0. 465; CRP ( / 1. 47( 1 , ? 9 CD ), _ T Z =- 1. 782aP = 0. 075b4 ( 2 CD, 1 UC) - l A V (K r 1 003 109 /L); X , “ % h z , l / b#645# h h 2010 M 7 19 7 Chin J GastroenterolHepato,l Jul 2010, Volnull19, Nonull7V 2 X - CD rTab2 Remicade! s efficacy in patientswithCD before and after treatment %

13、 h ESR CRP _ Y z - e a 7 51 87 a 3Q 4Q h 0 2 1 M 0 ah h , L Cl - E aL 10 12 3 m U . N2Q h , H L 5 1 1. 2 ( M )Sz - E a? 12 11 5. 7 3Q m ? 1 12,# 7 CD R * X (TopnulldownZ ) 13b F 7 F UC , 1 h , 4Q r * , 2 A h h ,* hM A z b 4 ( T , z 3 b1 CD UC r , (#646# h h 2010 M 7 19 7 Chin JGastroenterolHepato,l

14、Jul 2010, Volnull19, Nonull7 r T , UC 3 z bw , UC L , i , ? 3 i H , X 7 S p b7 CD y C E 5 , X ? P h | ,7 E % X 8 . N 5 b N , CD7 ,“ d “ 5 ? 8 = E . N B 5 , 5 y m , P X ? r h M ? 14b? S 0 8 O 1 “ 9b2 UC 7 S 3 mg/kg 0 , z A ,4 4 h b 12 IBD 5 mg/kg , ( r T b T 4 U , h ? S 0 | r p b1 UC B Q ? 4 0 r T z

15、f / ,4 4 , , | l r , 8 h ,9 8 f , 2 g 0 4 b* | IBD r T 1 o y 15, + Q ? * r T ? F 2 UC, 1 CD 4Q ,X r * ,7 6 2 CD, 3 UC 0 3Q , ? r * b4 U , X 0 1 4Q ,Z ? r * “ S b1 Q b F 14 , 51Q 0 , 1 3Q H ? 3 ( 4Q H C )b1 b n Q C bV F 14 0 f A , X - # H i f 4 V h $ A Q bh “ Q 9, 16b8 , X i CD v UC i r b CD7 ,* | m

16、(TopnulldownZ ) V ? z b B C 8 = 8 . N , n 5 m % E , X b F G UC , X r HW V ? , g z a , 8 0 Q ,2 0 4 , $ 0 , V ? CDM r b ? p h b I D 1 FaubionWA Jr, LoftusEV Jr, Harm senWS, eta.l The naturalhistoryof corticosteroid therapy for inflammatory boweldisease: a populationnullbased study J. Gastroenterology

17、, 2001, 121( 2): 255null260. 2 Rutgeerts P, Van Assche G, Vermeire S. Optimizing antinullTNF treatnullment in inflammatory boweldisease J. Gastroenterology, 2004, 126(6): 1593null1610. 3 Van den Brande JM, BraatH, van den Brink GR, et a.l Infliximabbutnot etanercept induces apoptosis in lam ina prop

18、ria Tnulllymphocytesfrom patients with Crohn! s disease J. Gastroenterology, 2003, 124(7): 1774null1785. 4 PresentDH, RutgeertsP, Targan S, eta.l Infliximab for the treatmentof fistulas in patientsw ith Crohn! s disease J. N EnglJM ed, 1999,340( 18): 1398null1405. 5 Hanauer SB, Feagan BG, Lichtenste

19、in GR, et a.l M aintenance inflixnullimab forCrohn! s disease: theACCENT % randomized trial J. TheLancet, 2002, 359(9317): 1541null1549. 6 Sands BE, Anderson FH, BernsteinCN, eta.l Infliximabmaintenancetherapy for fistulizingCrohn! s disease J. N EnglJM ed, 2004, 350(9): 876null885. 7 Rutgeerts P, V

20、an Assche G, Vermeire S. Review article: infliximabtherapy for inflammatory bowel diseasenullseven years on J. AlimentPharmacolTher, 2006, 23(4): 451null463.8 D h h s h x T F . S h ? S M i J. h , 2007, 12(8): 488null495. 9 ClarkM, ColombeiJF, Feagan BC, eta.l American GastroenterologicalAssociation

21、Consensus DevelopmentConference on the use ofbiologicsin the treatment of inflammatory bowel disease, June 21null23, 2006 J. Gastroenterology, 2007, 133(1): 312null339. 10 Nielsen OH, GionchettiP, AinsworthM, et a.l Rectaldialysate andfecal concentration ofneutrophil gelatinasenullassociated lipocal

22、in, internullleukinnull8, and tumor necrosis factornullalpha in ulcerative colitis J. AmJGastroentero,l 1999, 94( 10): 2923null2928. 11 Rutgeerts P, SandbornW J, Feagan BG, eta.l Infliximab andmaintenullnance therapy for ulcerative colitis J. N Engl JM ed, 2005, 353( 23): 2462null2476. 12 Wolters FL

23、, RusselMG, Stockbrugger RW. Systematic review: hasdisease outcome in Crohn! s disease changed during the last fourdecnullades? J. AlimentPharmacolTher, 2004, 20(5): 483null496. 13 BaertF, CaprilliR, AngelucciE, eta.l M edicaltherapy forCrohn!s disease: topnulldown or stepnullup J. Dig Dis, 2007, 25

24、 ( 3 ):260null266. 14 RegueiroM, SchrautW, BaidooL, eta.l Infliximab preventsCrohn!s disease recurrence after ileal resection J. Gastroenterology,2009, 136( 2): 441null450. 15 FroslieKF, Jahnsen J, M oum BA, et a.l M ucosalhealing in inflamnullmatory boweldisease: results from aNorwegian populationn

25、ullbases conullhort J. Gastroenterology, 2007, 133( 2): 412null422. 16 FidderH, Schnitzler F, FerranteM, et a.l Longnullterm safety of inflixnullimab for the treatment of inflammatory bowel disease: a singlenullcentercohort study J. Gut, 2009, 58(4): 501null508.#647# h h 2010 M 7 19 7 Chin J GastroenterolHepato,l Jul 2010, Volnull19, Nonull7